Skip to content
Parakho

RPG Life Sciences Ltd

NSE RPGLIFEBSE 532983

Q1 FY27, unaudited

Revenue
₹195.69 Cr
Profit after tax
₹30.76 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations195.69—707.52
Other income4.70—25.58
Total income200.39—733.10
Employee benefit expense37.76—141.48
Finance costs0.63—0.89
Depreciation & amortisation5.90—21.48
Total expenses158.93—582.80
Profit before tax41.46—154.20
Tax expense10.70—39.03
Profit after tax30.76—115.17
Total comprehensive income30.61—114.53
Earnings per share
Earnings per share, basic₹18.60₹18.08
Earnings per share, diluted₹18.60₹69.64

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

A transcript for the Q4 FY26 call was filed with the exchange; Parakho has not summarised it yet.

All quarters

Filings

12 shown · 73 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 08 Oct 2026.